Compare KDP & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KDP | ALNY |
|---|---|---|
| Founded | 1981 | 2002 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.4B | 42.1B |
| IPO Year | 2007 | 2004 |
| Metric | KDP | ALNY |
|---|---|---|
| Price | $25.48 | $319.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 28 |
| Target Price | $34.56 | ★ $471.93 |
| AVG Volume (30 Days) | ★ 9.1M | 1.0M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | 45.71 | ★ 206.88 |
| EPS | 1.53 | ★ 2.33 |
| Revenue | ★ $16,603,000,000.00 | $1,037,418,000.00 |
| Revenue This Year | $59.03 | $52.99 |
| Revenue Next Year | $14.33 | $31.77 |
| P/E Ratio | ★ $16.81 | $141.43 |
| Revenue Growth | 8.16 | ★ 22.88 |
| 52 Week Low | $24.88 | $205.87 |
| 52 Week High | $35.94 | $495.55 |
| Indicator | KDP | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 31.81 | 47.47 |
| Support Level | $25.03 | $302.52 |
| Resistance Level | $28.38 | $330.33 |
| Average True Range (ATR) | 0.63 | 10.95 |
| MACD | -0.08 | 1.74 |
| Stochastic Oscillator | 24.62 | 54.53 |
Keurig Dr Pepper was established in 2018 following a merger between Keurig Green Mountain Coffee and Dr Pepper Snapple. The company manufactures and distributes coffee systems (including coffee brewers and single-serve coffee pods) under the Keurig and Green Mountain brands, as well as ready-to-drink beverages including flavored (non-cola) sparkling soft drinks under well-known brands such as Dr Pepper, Snapple, and Canada Dry. The company controls production and route to market for its own brands through in-house manufacturing plants and distribution infrastructure and leverages these facilities to manufacture and distribute for third-party coffee and beverage brands via licensing and partnership agreements. The US and Canada make up 95% of revenue, with the rest from Mexico.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.